TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Corporate Logo

Change of 6.73% for Tracon Pharmaceuticals Inc (NASDAQ:TCON)’s short interest was reported. In January was announced TCON’s total 134,400 short interest by FINRA. Previously was reported down change of 6.73% from 144,100 shares. With Average volume 120,500, TCON’s former position will take 1 days to recover. Tracon Pharmaceuticals Inc float short is 0.93%.

TCON is hitting $0.82 during the last trading session, after increased 0.01%.Currently TRACON Pharmaceuticals, Inc. is downtrending after 63.33% change in last January 12, 2018. TCON has 151,298 shares volume. TCON underperformed the S&P500 by 63.33%.

TRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration , and fibrotic diseases.The firm is worth $24.49 million. The Company’s lead product candidate is TRC105, an endoglin antibody, which is in Phase III clinical trials for angiosarcoma; randomized Phase II clinical trials for renal cell carcinoma; Phase II clinical trials for soft tissue sarcoma; Phase II clinical trials for gestational trophoblastic neoplasia; Phase I/II clinical trials for hepatocellular carcinoma; Phase I clinical trial for lung cancer; Phase I/II clinical trials for breast cancer; and Phase I/II clinical trials for wet AMD.Last it reported negative earnings. The companyÂ’s other product candidates comprise TRC102, a small molecule that is in Phase II clinical trials for mesothelioma, Phase II clinical trials for glioblastoma, Phase I clinical trial for solid tumors and lymphomas, as well as Phase I clinical trial for lung cancer; and TRC253, a small molecule high affinity competitive inhibitor of wild type androgen receptor (AR) and multiple AR mutant receptors that is in Phase I/II clinical trials for the treatment prostate cancer.

For more TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) news released recently go to: Seekingalpha.com, Globenewswire.com, Benzinga.com, Benzinga.com or Globenewswire.com. The titles are as follows: “Tracon Pharmaceuticals’ (TCON) CEO Charles Theuer on Q4 2017 Results – Earnings Call Transcript – Seeking Alpha” released on February 28, 2018, “Analysis: Positioning to Benefit within PPL, Inseego, Scientific Games, Orgenesis, CUI Global, and TRACON Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results – GlobeNewswire” on December 31, 2018, “Daily Biotech Pulse: Mallinckrodt Faces FDA Panel, Reshape’s Earnings, Vapotherm To Debut – Benzinga” with a publish date: November 14, 2018, “30 Stocks Moving In Thursday’s Mid-Day Session – Benzinga” and the last “TRACON to Report Third Quarter 2018 Company Highlights and Financial Results on November 7, 2018 – GlobeNewswire” with publication date: October 31, 2018.

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.




Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *